Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia

• Main Authors: Yufei Zhao (Author), Wenrui Yang (Author), Xin Zhao (Author), Xiangrong Hu (Author), Jing Hu (Author), Xu Liu (Author), Jianping Li (Author), Lei Ye (Author), Youzhen Xiong (Author), Yang Yang (Author), Baohang Zhang (Author), Xiaoxia Li (Author), Xiawan Yang (Author), Yimeng Shi (Author), Guangxin Peng (Author), Yuan Li (Author), Huihui Fan (Author), Kang Zhou (Author), Liping Jing (Author), Li Zhang (Author), Fengkui Zhang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundEltrombopag (EPAG), an oral thrombopoietin receptor agonist (TPO-RA), has been proven to improve the hematologic response without increasing toxic effects as a first-line therapy combined with standard immunosuppressive treatment (IST) in adults with severe aplastic anemia (SAA). Neverthel...